Who are Cryosite's key clients?

Who are Cryosite's main clinical trial clients?

Here's a list of the top 10 Australian clinical trial industry sponsors, courtesy Austrade. They're ranked in order of trials being run:

1. Novartis/Market Cap $US199b

2. Merck/MC $216b

3. Abbvie/MC $110b

4. Roche/MC $209b

5. Bristol Myers/MC $84b

6. Johnson & Johnson/MC $357b

7. Gilead Sciences/MC $83b

8. GlaxoSmithKline/MC $242b

9. Pfizer/MC $201b

10. Amgen/MC $122b

While Cryosite is reluctant to identify its key sources of business, clinical trial sources say most - if not all - of the blue chip global operators listed above are clients of CTE.

On my calculations the combined market cap of Cryosite clients exceeds $US1.8 trillion.

That's a tribute to the under-reported, under-recognised Australian clinical trials industry. And, of course, it's a tribute to Cryosite.

I think it's a profound pity the group hides bright lights - and brilliant successes - under the proverbial bushel.

Further underlines why CTE's MC should be more than a tad above $A2.1m.